AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Dianthus Therapeutics, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00FB2NQ15
76.78▼ 1.75 (-2.23%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
78.53
Day's Range
76.02 – 78.16
52-Week Range
32.22 – 117.88
Volume
379.2K
Avg Volume
985.0K
Share Statistics
Shares Outstanding
Employees
92
Exchange
XNAS
Listed
2023-09-12
Share count as of August 3, 2026

Dianthus Therapeutics, Inc. Common Stock (DNTH) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Dianthus Therapeutics, Inc. Common Stock (DNTH)
What is Dianthus Therapeutics, Inc. Common Stock's Market Cap?
Dianthus Therapeutics, Inc. Common Stock's Market Cap is $4.3B, based on as-reported figures from SEC (XBRL) filings.
What is Dianthus Therapeutics, Inc. Common Stock's Enterprise Value?
Dianthus Therapeutics, Inc. Common Stock's Enterprise Value is $3.4B, based on as-reported figures from SEC (XBRL) filings.
What is Dianthus Therapeutics, Inc. Common Stock's Price / Sales?
Dianthus Therapeutics, Inc. Common Stock's Price / Sales is 2109.4×, based on as-reported figures from SEC (XBRL) filings.
What is Dianthus Therapeutics, Inc. Common Stock's EV / Revenue?
Dianthus Therapeutics, Inc. Common Stock's EV / Revenue is 1673.8×, based on as-reported figures from SEC (XBRL) filings.
What is Dianthus Therapeutics, Inc. Common Stock's EV / EBITDA?
Dianthus Therapeutics, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Dianthus Therapeutics, Inc. Common Stock's Revenue (TTM)?
Dianthus Therapeutics, Inc. Common Stock's Revenue (TTM) is $2.0M, based on as-reported figures from SEC (XBRL) filings.
What is Dianthus Therapeutics, Inc. Common Stock's Net Income (TTM)?
Dianthus Therapeutics, Inc. Common Stock's Net Income (TTM) is -$192.2M, based on as-reported figures from SEC (XBRL) filings.
What is Dianthus Therapeutics, Inc. Common Stock's EBITDA?
Dianthus Therapeutics, Inc. Common Stock's EBITDA is -$217.7M, based on as-reported figures from SEC (XBRL) filings.
What is Dianthus Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Dianthus Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -3.44, based on as-reported figures from SEC (XBRL) filings.
What is Dianthus Therapeutics, Inc. Common Stock's EBITDA Margin?
Dianthus Therapeutics, Inc. Common Stock's EBITDA Margin is -10693.6%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · DNTHAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues:
Revenues
YoY growth+294.3%-60.2%-78.6%-81.8%
Operating expenses:
Research and development
General and administrative
Total operating expenses
% of revenue8179.1%10150.3%24586.3%10273.7%
Loss from operations
% of revenue-8079.1%-10050.3%-24486.3%-10173.7%
Other income/(expense):
Interest and investment income
Gain/(loss) on investment in former related party——
Loss on currency exchange, net
Other expense
Total other income
Net loss
% of revenue-6598.6%-8819.4%-22687.3%-9284.1%
Net loss per share attributable to common stockholders, basic
Net loss per share attributable to common stockholders, diluted